Studies have shown that TNBC patients with high MAL2 expression have a poorer prognosis, with a significantly lower 5-year survival rate (71.33% vs 89.59%, p = 0.0224), independent of PD-1 expression levels and clinical pathological features of the tumor (Borowczak et al., 2024). This evidence concerns the gene MAL2 and neoplasm.